Estimating Agonist Efficacy by Engineering Acetylcholine Receptor-Channels  by Jadey, Snehal V. et al.
274a Monday, March 7, 20111491-Pos Board B401
Nicotinic Receptors Investigated Using a Next Generation Automated
Patch Clamp System
Juliette Johnson.
A number of nicotinic acetycholine receptors (nAChR) are being actively used
as ion channel drug targets. These measurements pose unique challenges for
automated patch clamp instrumentation. This is due to the fast kinetics of
a number of nAChR ion channel types, as well as the need to limit the agonist
exposure time across a large number of parallel recordings in order to control
desensitization.
In this study we present data relating to the fast recovery from desensitization
that, for a next generation automated patch clamp platform, is mediated by con-
tinuous flow and microfluidic compound delivery. EC50 data for known ago-
nists will be presented, along with reference compound data.
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Interaction of 18-Methoxycoronaridine with Nicotinic Acetylcholine
Receptors in Different Conformational States
Anita E. Shamoun, Avraham Rosenberg, Dominik Feuerbach, Katarzyna
M. Targowska-Duda, Krzysztof Jozwiak, Ruin Moaddel, Stanley D. Glick,
Irving W. Wainer, Hugo R. Arias.
The interaction of 18-methoxycoronaridine (18-MC) with nicotinic acetyl-
choline receptors (AChRs) was compared with that for ibogaine and phency-
clidine (PCP). The results established that 18-MC: (a) is more potent than
ibogaine and PCP inhibiting (5)-epibatidine-induced AChR Ca2þ influx.
The potency of 18-MC is increased after longer pre-incubation periods,
which is in agreement with the enhancement of [3H]cytisine binding to rest-
ing but activatable Torpedo AChRs, (b) binds to a single site in the Torpedo
AChR with high affinity and inhibits [3H]TCP binding to desensitized AChRs
in a steric fashion, suggesting the existence of overlapping sites. This is sup-
ported by our docking results indicating that 18-MC interacts with a domain
located between the serine (position 6’) and valine (position 13’) rings, and
(c) inhibits [3H]TCP, [3H]ibogaine, and [3H]18-MC binding to desensitized
AChRs with higher affinity compared to resting AChRs. This can be partially
attributed to a slower dissociation rate from the desensitized AChR compared
to that from the resting AChR. The enthalpic contribution is more important
than the entropic contribution when 18-MC binds to the desensitized AChR
compared to that for the resting AChR, and vice versa. Ibogaine analogs in-
hibit the AChR by interacting with a luminal domain that is shared with PCP,
and by inducing desensitization.
Support: Science Foundation Arizona
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The Binding Site for 17b-Estradiol Can be Placed on Any Subunit of a Nic-
otinic a4b2 Receptor
Xiaochun Jin, Joe Henry Steinbach.
Endogenous steroids can modulate the activity of transmitter-gated channels
by directly interacting with the receptor. 17b-Estradiol potentiates activation
of neuronal nicotinic a4b2 receptors by interacting with a 4 amino-acid se-
quence at the extreme carboxy-terminus of the a4 subunit. Nicotinic recep-
tors are pentamers of related subunits, and contain 2 binding sites for
acetylcholine at interfaces between an a4 and a b2 subunit. It is not known
whether potentiation requires that the sequence be placed on a specific sub-
unit (e.g. an a4 subunit which is involved in forming an acetylcholine-bind-
ing site). By using concatemers of subunits and chimeric subunits, we have
found that the recognition sequence can be moved from the a4 to the b2 sub-
unit and still result in equivalent potentiation. The sequence also can be
placed on an acetylcholine-binding subunit or on the 5th (structural) subunit.
The amount of potentiation increases with increasing numbers of copies of
the binding site in the assembled pentamer. The data indicate that the estra-
diol-binding sequence is a discrete element, and suggest that the effect of
17b-estradiol is mediated by actions on single subunits and that the overall
consequences for gating occur due to the summation of independent energetic
contributions to overall gating of this receptor. Supported by NIH NS22356
& GM47969.1494-Pos Board B404
Interaction of Tricyclic Antidepressants with the Ha3b4 Nicotinic Recep-
tor
Dominic Williams, Ali H. Ahmad, Katarzyna M. Targowska-Duda,
Dominik Feuerbach, Krzysztof Jozwiak, Hugo R. Arias.
The interaction of tricyclic antidepressants (TCAs) with human (h)a3b4 nico-
tinic acetylcholine receptor (AChR) was compared to that for mecamylamine.The results established that: (a) [3H]imipramine binds to a single site with high
affinity (Kd = 0.415 0.04 mM), (b) imipramine inhibits [3H]imipramine bind-
ing to resting AChR with the same affinity as to desensitized AChR, suggesting
that TCAs do not distinguish between these conformational states, (c) imipra-
mine inhibits [3H]ibogaine binding, suggesting mutual interaction between
both compounds, (d) both TCAs and mecamylamine inhibit (5)-epibatidine-
induced Ca2þ influx with potencies in the same concentration range, but
only TCAs inhibit [3H]imipramine binding to ha3b4 AChRs. This is supported
by our molecular docking results, where imipramine, in the neutral and proton-
ated states, interacts with the leucine (position 9’) and valine/phenylalanine
(position 13’) rings, while protonated mecamylamine interacts with the outer
ring (position 20’). Our data suggest that TCAs and ibogaine bind to overlap-
ping sites located between the serine and valine/phenylalanine rings in the
ha3b4 AChR ion channel, while protonated mecamylamine can be attracted
to the channel mouth before blocking ion flux by interacting with a luminal
site in its neutral state.1495-Pos Board B405
Estimating Agonist Efficacy by Engineering Acetylcholine Receptor-Chan-
nels
Snehal V. Jadey, Prasad Purohit, Iva Bruhova, Timothy Gregg,
Anthony Auerbach.
Nicotinic acetylcholine receptor-channels (AChRs) are allosteric proteins that
spontaneously isomerize (‘gate’) between a resting, closed-channel conforma-
tion (R) and an active, open-channel one (R*). Different agonists promote the
R-R* conformational change to different extents because they experience dif-
ferent degrees of affinity change at the agonist binding site. The affinity ratio,
R/R*, is the parameter that determines the gating equilibrium constant E2 and,
hence, efficacy. The most accurate way to estimate E2 is by using single-chan-
nel, patch-clamp electrophysiology. However, we wanted to examine ligand/re-
ceptor combinations that have gating rate constants either too-fast or too-slow
for such analysis. In this study we describe and use a stepwise perturbation
method involving mutations, depolarization and partial agonists to circumvent
problems associated with the bandwidth limitations of patch electrophysiology
and channel block by agonist molecules, in order to determine accurately rate
constants at single channel level of seven agonists with varying efficacies. Our
estimates for known agonists, obtained by using this method are in excellent
agreement with previously published values. This shows that the effects on gat-
ing from the perturbations we employed are the same regardless of the activat-
ing agonist and, conversely, the effects of the agonist are independent of the
perturbations. The ‘improved’ gating constant estimates for ACh on wild
type, adult mouse neuromuscular AChRs (100 mV, 23 oC, expressed in
HEK cells) are: opening rate: 66,000 s1, closing rate: 2300 s1, and equilib-
rium: 29.1496-Pos Board B406
Molecular Thermography: Mapping Enthalpy and Entropy Changes in
Acetylcholine Receptor Gating
Shaweta Gupta, Anthony Auerbach.
We studied enthalpy and entropy changes in AChR gating from the temper-
ature dependence of the gating rate and equilibrium constants estimated from
the single-channel currents from wild type and mutant AChRs activated by
different agonists (acetylcholine , choline, carbachol or none) (5-35oC,
HEK cells, cell attached , 110 mV , mouse a[[Unsupported Character -
]]bde). The mutations were between the binding sites and the gate, in the
a-subunit [W149, G153, A96, Y127, E45, P272, P265 and C418] or the d-
subunit [V269 and L265]. The forward and reverse isomerization rate con-
stants were temperature-dependent (activation enthalpy ~21 kcal/mol;
Q10~3.8). For aG153S, aW149T, aP272G and three different agonists the
free energy change (aaGo, at 25oC) and the enthalpy change (aaHo) were
approximately equal. These values differed by >2 kcal/mol for aY127C/E,
aW149F/N/R and dV269C/A. The slope of the rate-equilibrium free energy
relationship (F) for residues aW149 and dV269 was constant with tempera-
ture, and the slope for the enthalpy component of this relationship was equal
to F. The results suggest that the map of gating enthalpy changes consequent
to mutation are different than that for free energy changes. We speculate that
the changes in enthalpy are mainly local to the site of perturbation and that
we can make a residue-by-residue map of heat absorption and emission in
AChR gating (a ‘molecular thermogram’).
